Prothena Corp. (NASDAQ: PRTA) reported Q2 EPS of ($0.46), $0.42 better than the analyst estimate of ($0.88). Revenue for the quarter came in at $26.8 million versus the consensus estimate of $15.09 million.

• Net cash used in operating and investing activities was $36.3 million in the second quarter and $76.5 million for the first six months of 2017; quarter-end cash and restricted cash position of $475.8 million, provides funding to advance diverse pipeline
• Initiated, with Roche, the global Phase 2 PASADENA study of PRX002/RG7935 in patients with early Parkinson’s disease, triggering a $30 million milestone payment from Roche to Prothena
• Completed enrollment in the Phase 3 VITAL Amyloidosis Study evaluating NEOD001 in newly diagnosed, treatment naïve patients with AL amyloidosis and cardiac dysfunction
• Strengthened management team with appointments of Sarah Noonberg, MD, PhD as Chief Medical Officer and Wagner Zago, PhD as Chief Scientific Officer

For earnings history and earnings-related data on Prothena Corp. (PRTA) click here.